Updates are available Correction dated 2022-04-05
Click to view Correction: https://doi.org/10.1038/s41467-022-29700-y
-
Authors
Rosen, Ezra Y.
Won, Helen H.
Zheng, Youyun https://orcid.org/0000-0002-4507-2708
Cocco, Emiliano https://orcid.org/0000-0002-1397-2656
Selcuklu, Duygu
Gong, Yixiao
Friedman, Noah D.
de Bruijn, Ino https://orcid.org/0000-0001-5427-4750
Sumer, Onur https://orcid.org/0000-0001-9726-9441
Bielski, Craig M.
Savin, Casey
Bourque, Caitlin
Falcon, Christina
Clarke, Nikeysha
Jing, Xiaohong
Meng, Fanli
Zimel, Catherine
Shifman, Sophie
Kittane, Srushti
Wu, Fan https://orcid.org/0000-0002-3960-320X
Ladanyi, Marc
Ebata, Kevin
Kherani, Jennifer
Brandhuber, Barbara J.
Fagin, James https://orcid.org/0000-0002-2365-2517
Sherman, Eric J.
Rekhtman, Natasha
Berger, Michael F. https://orcid.org/0000-0003-3882-5000
Scaltriti, Maurizio
Hyman, David M. https://orcid.org/0000-0001-8150-9762
Taylor, Barry S.
Drilon, Alexander https://orcid.org/0000-0001-6806-9061
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA009512, CA008748, CA160001, CA207244, CA204749, CA245069, CA251591)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
MSK scholar prize
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 19 February 2021
Accepted: 11 February 2022
First Online: 18 March 2022
Change Date: 5 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-022-29700-y
Competing interests
: E.Y.R. received research funding from Bayer. M.F.B. received honoraria from Roche and research funding from Grail outside of this work. He is also a co-inventor on a provisional patent application for systems and methods for detecting cancer via cfDNA screening. A.D. received honoraria for advisory board activities for Ignyta/Genentech/Roche, Loxo/Bayer/Eli Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, Remedica Ltd., ArcherDX, Monopteros; and research funding from Pfizer, Exelixis, GlaxoSmithKlein, Teva, Taiho, PharmaMar, Foundation Medicine; royalties from Wolters Kluwer; and miscellaneous expenses from Merck, Puma, Merus, and Boehringer Ingelheim. M.S. is an employee of AstraZeneca. D.M.H. is an employee of Loxo Oncology, a wholly-owned subsidiary of Eli Lilly. H.H.W. and B.S.T. are currently employees of Loxo Oncology, a wholly-owned subsidiary of Eli Lilly. B.S.T. reports receiving honoraria and research funding from Genentech and advisory board activities for Boehringer Ingelheim. All stated activities were outside of the work described herein. No other disclosures were noted.
